ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT04471974 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Castration-Resistant Prostate Carcinoma
Metastatic Prostate Adenocarcinoma
Metastatic Prostate Small Cell Carcinoma
Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8

Interventions

DRUG: BET Bromodomain Inhibitor ZEN-3694
DRUG: Enzalutamide
BIOLOGICAL: Pembrolizumab

Sponsor

Rahul Aggarwal

Collaborators

[object Object]
[object Object]
[object Object]